Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for Louise Gardner�
+0.06 (0.17%)
Real-time:   11:46AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.43 - 36.56
52 week 31.56 - 42.50
Open 35.43
Vol / Avg. 269,532.00/652,838.00
Mkt cap 2.53B
P/E 24.66
Div/yield     -
EPS 1.44
Shares 71.12M
Beta 0.80
Inst. own 136%
May 4, 2015
Q3 2015 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Myriad Genetics Inc at Barclays Healthcare Conference
Feb 12, 2015
Myriad Genetics Inc at Leerink Global Healthcare Conference
Feb 3, 2015
Q2 2015 Myriad Genetics Inc Earnings Call - Webcast
Feb 3, 2015
Q2 2015 Myriad Genetics Inc Earnings Release
Jan 12, 2015
Myriad Genetics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 13.03% 22.64%
Operating margin 19.71% 35.27%
EBITD margin - 37.04%
Return on average assets 12.12% 21.65%
Return on average equity 13.71% 24.35%
Employees 1,649 -
CDP Score - -


320 Wakara Way
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Peter D. Meldrum President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 82
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Jayne B. Hart Executive Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 58
Bio & Compensation  - Reuters
Ronald S. Rogers Executive Vice President - Corporate Communications
Age: 46
Bio & Compensation  - Reuters
Robert Gardner Harrison Chief Information Officer
Age: 48
Bio & Compensation  - Reuters
Jerry S. Lanchbury Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters